Unecritinib (TQ‐B3101), as the first‐line therapy for ROS1 fusion‐positive Chinese NSCLC patients, showed an ORR of 78.4% and a median PFS of 15.6 months, suggesting good efficacy and manageable toxicity [32]. Here, ROS1 is linked to non-small cell lung carcinoma.